Biotech · Private company · Durham, NC, US

Aimmax Therapeutics, Inc.

Track this companyFree. Adds Aimmax Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant GonorrheaFiscal year 2025 · $1MNIH RePORTER 5R44AI170150-04 · fetched Nov 12, 2026
A Single Dose Therapy to Treat Drug Resistant GonorrheaFiscal year 2024 · $306.5KNIH RePORTER 1R44AI184024-01 · fetched Nov 12, 2026
Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive InfectionsFiscal year 2024 · $307KNIH RePORTER 5R43AI174384-02 · fetched Nov 12, 2026
Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant GonorrheaFiscal year 2024 · $1MNIH RePORTER 5R44AI170150-03 · fetched Nov 12, 2026